CAMLINFINECamlin Fine Sciences Ltd.
Camlin Fine Sciences Q2 FY27 Results: Consolidated Net Loss ₹28.08 Crore on Total Income of ₹496 Crore
- Earnings
- specialty chemicals
Reviewed byRachit TripathiBlacklitt Research
Camlin Fine Sciences (NSE: CAMLINFINE) reported a consolidated net loss of ₹28.08 crore and total income of ₹496.42 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹249.12 crore with a net loss of ₹20.01 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹496.42 crore, up 9.2% YoY and down 4.8% QoQ
- Net profit: Loss of ₹28.08 crore against a profit of ₹5.90 crore a year earlier
- EPS: Basic loss of ₹1.45 per share, against a loss of ₹0.77 a year earlier
- Finance costs: ₹20.59 crore, up 15.4% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹249.12 crore, down 2.0% YoY and up 11.3% QoQ
- Net profit: Loss of ₹20.01 crore against a loss of ₹3.64 crore a year earlier
- EPS: Basic loss of ₹1.04 per share, against a loss of ₹0.19 a year earlier
- Other income: ₹4.54 crore, down 55.5% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 496.42 | 454.53 | +9.2% | 521.22 | -4.8% | |
| Revenue from operations | 491.46 | 450.26 | +9.2% | 519.88 | -5.5% |
| Other income | 4.96 | 4.26 | +16.3% | 1.34 | +269.9% |
| -28.08 | 5.90 | n/a | -31.80 | +11.7% | |
| Profit before tax | -34.89 | 4.03 | n/a | -32.26 | -8.1% |
| Finance costs | 20.59 | 17.85 | +15.4% | 14.01 | +47.0% |
| Depreciation | 19.92 | 17.66 | +12.8% | 19.16 | +4.0% |
| Tax expense | -6.81 | 0.28 | n/a | -0.46 | n/a |
| Net profit margin | -5.66% | 1.30% | -6.95 pp | -6.10% | +0.44 pp |
| EPS, basic (₹) | -1.45 | -0.77 | -88.3% | -1.65 | +12.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The consolidated loss widened from the year-earlier profit even though revenue from operations rose 9.2%. Other income of ₹4.96 crore is 1.0% of total income, so operating revenue carries the quarter. Finance costs of ₹20.59 crore are 4.1% of total income, up 15.4% YoY.
Consolidated net profit rose 11.7% QoQ while total income fell 4.8%.
The filing lists exceptional expenses of ₹1.93 crore on the Vinpai open offer and a loss of ₹1.62 crore from discontinued operations of CFS Wanglong Flavours (Ningbo).
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 249.12 | 254.24 | -2.0% | 223.89 | +11.3% | |
| Revenue from operations | 244.58 | 244.04 | +0.2% | 222.49 | +9.9% |
| Other income | 4.54 | 10.19 | -55.5% | 1.40 | +223.5% |
| -20.01 | -3.64 | -449.8% | -12.31 | -62.5% | |
| Profit before tax | -31.17 | -3.81 | -718.2% | -18.67 | -67.0% |
| Finance costs | 15.49 | 18.73 | -17.3% | 13.38 | +15.7% |
| Depreciation | 13.79 | 13.47 | +2.4% | 13.51 | +2.1% |
| Tax expense | -11.17 | -0.17 | n/a | -6.36 | -75.6% |
| Net profit margin | -8.03% | -1.43% | -6.60 pp | -5.50% | -2.53 pp |
| EPS, basic (₹) | -1.04 | -0.19 | -447.4% | -0.64 | -62.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone revenue from operations rose 0.2% YoY, but other income fell 55.5% from ₹10.19 crore to ₹4.54 crore, and the standalone loss before tax widened to ₹31.17 crore from ₹3.81 crore.
Standalone net profit fell 62.5% QoQ while total income rose 11.3%. Tax expense was a credit of ₹11.17 crore, against a credit of ₹0.17 crore a year earlier. Finance costs of ₹15.49 crore are 6.2% of total income, down 17.3% YoY.
The standalone and consolidated results carry unmodified limited review conclusions from Kalyaniwalla & Mistry LLP. The filing does not give the reason for the consolidated loss or for the fall in standalone profit before tax.
Inference
The Board approved a rights issue of equity shares of face value ₹1 each for an amount not exceeding ₹250 crore. The filing says the record date, issue price and rights entitlement ratio will be determined later by the Board or the Securities Issue and Allotment Committee, subject to statutory and regulatory approvals.
SEBI issued an administrative warning letter dated 29 Oct 2026 for violation of the Listing Regulations. The filing does not say what the letter requires of the company or which disclosure it concerns.
Not stated: the effect of this purchase on future results, and when the Diphenol plant at Dahej will restart.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
